BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 37094558)

  • 1. Safety and Efficacy of Ticagrelor versus Clopidogrel in East Asian Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Treated with Dual Antiplatelet Therapy: A Meta-Analysis of Randomized Controlled Trials.
    Li J; Wang Q; Wu C; Qu X; Zhang L; He X; Ma S; Qiu M; Wang X
    Cardiology; 2023; 148(4):363-373. PubMed ID: 37094558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis.
    De Filippo O; Piroli F; Bruno F; Bocchino PP; Saglietto A; Franchin L; Angelini F; Gallone G; Rizzello G; Ahmad M; Gasparini M; Chatterjee S; De Ferrari GM; D'Ascenzo F
    BMJ Evid Based Med; 2024 May; 29(3):171-186. PubMed ID: 38242567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
    Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
    Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bleeding risk in patients prescribed dual antiplatelet therapy and triple therapy after coronary interventions: the ADAPTT retrospective population-based cohort studies.
    Harris J; Pouwels KB; Johnson T; Sterne J; Pithara C; Mahadevan K; Reeves B; Benedetto U; Loke Y; Lasserson D; Doble B; Hopewell-Kelly N; Redwood S; Wordsworth S; Mumford A; Rogers C; Pufulete M
    Health Technol Assess; 2023 May; 27(8):1-257. PubMed ID: 37435838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.
    Ge Z; Kan J; Gao X; Raza A; Zhang JJ; Mohydin BS; Gao F; Shao Y; Wang Y; Zeng H; Li F; Khan HS; Mengal N; Cong H; Wang M; Chen L; Wei Y; Chen F; Stone GW; Chen SL;
    Lancet; 2024 May; 403(10439):1866-1878. PubMed ID: 38599220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of ticagrelor and clopidogrel in East Asian patients with coronary artery disease undergoing percutaneous coronary intervention.
    Li J; Qiu H; Yan L; Guo T; Wang Y; Li Y; Zheng J; Tang Y; Xu B; Qiao S; Yang Y; Gao R
    Curr Med Res Opin; 2020 Nov; 36(11):1739-1745. PubMed ID: 32945695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Ticagrelor With Clopidogrel in East Asian Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Ma Y; Zhong PY; Shang YS; Bai N; Niu Y; Wang ZL
    J Cardiovasc Pharmacol; 2022 May; 79(5):632-640. PubMed ID: 35091511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: Systematic review and meta-analysis.
    Misumida N; Aoi S; Kim SM; Ziada KM; Abdel-Latif A
    Cardiovasc Revasc Med; 2018 Sep; 19(6):689-694. PubMed ID: 29452843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration and kind of dual antiplatelet therapy for acute coronary syndrome patients: a network meta-analysis.
    D'Ascenzo F; DE Filippo O; Angelini F; Piroli F; DE Lio G; Bocchino PP; Baldetti L; Melillo F; Chieffo A; Saglietto A; Omedè P; Montefusco A; Conrotto F; de Ferrari GM
    Minerva Cardiol Angiol; 2023 Oct; 71(5):494-503. PubMed ID: 35332750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel de-escalation antiplatelet therapy for patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Li Y; Lei M; Yang Y; An L; Zhou H; Wang J; Zhao Z; Wang X; Nie S; Wang X; Hau WK; Xue Z
    Medicine (Baltimore); 2023 Jul; 102(27):e34153. PubMed ID: 37417626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a 'target trial'.
    Pufulete M; Harris J; Pouwels K; Reeves BC; Lasserson D; Loke YK; Mumford A; Mahadevan K; Johnson TW
    Open Heart; 2022 Aug; 9(2):. PubMed ID: 35961692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De-escalation from Prasugrel or Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome Managed with Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Clinical Trials.
    Abdelazeem B; Shehata J; Abbas KS; El-Shahat NA; Baral N; Adhikari G; Khan H; Hassan M
    Am J Cardiovasc Drugs; 2022 May; 22(3):287-298. PubMed ID: 34651261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Wang HY; Li Y; Xu XM; Li J; Han YL
    Chin Med J (Engl); 2018 Sep; 131(17):2017-2024. PubMed ID: 30127210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis.
    Wu H; Xiang X; Li D; Shen S; Li X
    Curr Pharm Des; 2020; 26(46):5988-5997. PubMed ID: 32534561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Ticagrelor versus Clopidogrel in Patients with Coronary Bifurcation Lesions Undergoing Percutaneous Coronary Intervention.
    Zheng W; Li Y; Tian J; Li L; Xie L; Mao Q; Tong W; Zhou D; Azzalini L; Zhao X
    Biomed Res Int; 2019; 2019():3170957. PubMed ID: 31016189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of major adverse cardiovascular events of
    Biswas M; Kali MSK; Biswas TK; Ibrahim B
    Platelets; 2021 Jul; 32(5):591-600. PubMed ID: 32664772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Individual Patient Data Meta-Analysis of TWILIGHT and TICO Randomized Trials.
    Baber U; Jang Y; Oliva A; Cao D; Vogel B; Dangas G; Sartori S; Spirito A; Smith KF; Branca M; Collier T; Pocock S; Valgimigli M; Kim BK; Hong MK; Mehran R
    Circulation; 2024 Feb; 149(8):574-584. PubMed ID: 37870970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Ticagrelor in East Asian Patients with Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
    Xie C; Lin J; Qin Q; Zhu J
    Anatol J Cardiol; 2022 Jun; 26(6):434-441. PubMed ID: 35703479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Galli M; Benenati S; Capodanno D; Franchi F; Rollini F; D'Amario D; Porto I; Angiolillo DJ
    Lancet; 2021 Apr; 397(10283):1470-1483. PubMed ID: 33865495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prasugrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis of Randomized Trials.
    Ray A; Najmi A; Khandelwal G; Jhaj R; Sadasivam B
    Cardiovasc Drugs Ther; 2021 Jun; 35(3):561-574. PubMed ID: 32816142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.